Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Why Abbvie Might Be Poised for a Return to Profitability

Chevron

Bristol-Myers

Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial) ( BRK.B , Financial) published its fourth-quarter 13F on Monday.

Buffett Still Likes Chevron, Continues to Sell Health Care

We're trimming AbbVie on Tuesday, with shares up to a new all-time high. We also see news on Boeing as "priced in" already.

Investing Club: We're locking in a profit on this drug stock (and looking at the Boeing news)

Charter Communications

Kroger

Mastercard

Marsh & McLennan

Royalty Pharma

Sirius XM Holdings Inc

Teva Pharmaceutical

Visa

Warren Buffett once again was a net seller of equities in the fourth quarter, slicing, slashing and outright exiting stakes across a series of sectors that have fallen out of his favor. But the Oracle of Omaha did pull off a few interesting buys in Q4, too.

10 Stocks Warren Buffett Is Selling

Avis Budget Group

Toronto-Dominion Bank

Sea Ltd, AbbVie, Toronto Dominion Bank and Avis Budget were our top stock trades for Tuesday. Here's how the charts look now.

4 Top Stock Trades for Tuesday: SE, ABBV, TD, CAR

Caterpillar

Johnson & Johnson

Lowe's

NextEra Energy

Nucor

Exxon Mobil

Dividend aristocrats are companies that have raised dividend payments at least once a year for the past 25 years. The post 7 Dividend Aristocrats That Could Outpace This Volatile Market appeared first on InvestorPlace.

7 Dividend Aristocrats That Could Outpace This Volatile Market

No matter how long is the time you dedicate to look at/hold AbbVie, it's a "movie" with a happy ending, with a second-to-none acting performance. In spite of near-future growth concerns, and even if the stock might be (technically/optically) looking fully valued, we believe that there's still meat left on the AbbVie bone.

AbbVie - A Biotech, Oscar Winning Movie

Amgen

Sanofi

Vertex Pharmaceuticals

Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.

Will the Rally of These 5 Big Drugmakers Continue in 2022?

AbbVie routinely meets and slightly beats ambitious growth targets, as it demonstrated again in its Q4, 2021 earnings call.

AbbVie: Portfolio Topper - Try It You'll Like It

Innovative Industrial Properties

Not only do they pay high yields, they also have plenty of growth opportunities on the horizon.

2 Dividend Stocks That Are Better Investments Than AT&T

WASHINGTON, Feb. 10, 2022 /PRNewswire/ -- Healis Therapeutics, a privately held biotechnology company, today announces its ownership of a key botulinum toxin patent from AbbVie (NYSE: ABBV). After clinically significant results in early trials, Allergan acquired the rights to develop botulinum toxin for depression in 2013.

Healis Therapeutics acquires ownership of key botulinum toxin patent

AbbVie is a big pharma powerhouse that refuses to be derailed by the patent expiry of its lead asset - the world's best selling drug Humira. Management has a plan in place to replace declining revenues of the mega blockbuster while still growing the business at a CAGR of ~4.5%.

AbbVie: Superb 2021 Paves Way For Further Outperformance In 2022

The stock price of AbbVie Inc (NYSE: ABBV) increased by 0.69% in the most recent trading session. This is why it happened.

AbbVie (ABBV) Stock: Why The Price Increased

Inmode Ltd

Whether you're looking for growth or big dividends, the healthcare sector's got deals galore.

3 Top Healthcare Stocks to Buy for February

IRVINE, Calif., Feb. 8, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the FDA approval of JUVÉDERM® VOLBELLA® XC for improvement of infraorbital hollows in adults over the age of 21.2 According to clinical trial data, 90% of subjects reported satisfaction through one year after treatment.2 With this approval, Allergan Aesthetics continues the expansion of its treatment portfolio to better address unmet patient needs.

FDA Approves JUVÉDERM® VOLBELLA® XC For Undereye Hollows

Even as the market reversed course, some stocks continued to outperform.

These 2 Mega-Cap Stalwart Stocks Just Hit All-Time Highs

Rinvoq was recently authorized in the U.S. as a treatment for patients with moderate-to-severe eczema.

AbbVie Wins Yet Another Approval for This Drug

AbbVie offers Growth Potential, High-Yield, and Strong Dividend Growth. The company has long been led by the #1 selling drug in the world in Humira, but they are now taking a more diversified approach.

AbbVie Stock: Get In On This Investor Trifecta

Advanced Micro Devices

NVIDIA

QUALCOMM

AMD, Nvidia, Facebook, Qualcomm and AbbVie were our top stock trades for Thursday. Here's how the charts are setting up now.

5 Top Stock Trades for Thursday: AMD, NVDA, FB, QCOM, ABBV

AbbVie (NYSE: ABBV) reports $3.31 EPS in the fourth quarter, which tops the $3.28 analyst estimate by $0.03. However, the company recorded $14.89 billion in revenue in the same quarter, a little less than the $14.95 billion consensus estimate.

AbbVie tops fourth-quarter estimates by 3%

AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q4 2021 Results - Earnings Call Transcript

AbbVie (ABBV) beats fourth-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales.

AbbVie's (ABBV) Q4 Earnings Surpass Estimates, Sales Miss

Despite some spotty results here and there, we saw strength in all the right places in AbbVie's fourth-quarter earnings report.

Cramer's Investing Club: We're encouraged AbbVie shares held recent gains after a mixed quarter

Shares of AbbVie (NYSE: ABBV) fell in the wake of the Q4 results because the results were a little mixed in relation to the analyst's estimates. That dip resulted in a buy signal for the broader market, however, because mixed as they were, the results are strong, the outlook is positive, the dividend is safe, and AbbVie presents a deep value compared to the S&P 500.

High-Yield, Deep-Value AbbVie Confirms Uptrend

AbbVie (ABBV) delivered earnings and revenue surprises of 0.61% and 0.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

News for AbbVie Stock (ABBV)